Inflammation & treatment response in lung cancer immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how inflammation and body changes (like weight loss) affect how well immunotherapy works in lung cancer. If you are starting immunotherapy at the hospital in Tours, your doctors will collect information from your regular care to learn more about your response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have lung cancer (any type and any stage).
- You are about to start or have just started an immune checkpoint inhibitor (a type of immunotherapy, possibly combined with chemotherapy).
- You are receiving care at the University Hospital of Tours (CHRU de Tours).
- You are not under legal guardianship or protective supervision, and you agree to let the researchers use your medical data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and sputum (phlegm) samples from people with lung cancer before and during immunotherapy. The goal is to see if certain immune markers in these samples can predict how well the treatment works.
This study looks at using blood and imaging markers to predict if patients with lung cancer who receive both immunotherapy and chest radiation will develop lung inflammation (called radiation lung injury). It may help doctors personalise care and reduce side effects.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study is a survey to learn about the experiences and feelings of people with non-small cell lung cancer who are taking immunotherapy drugs. The goal is to understand how you're doing on treatment, which can help improve care for others.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.